Skip J.F. Young; David G. Huff
Vancouver Aquarium, Canada's Pacific National Aquarium, in Stanley Park,
Vancouver, British Columbia, Canada
Captive breeding management through chemical contraception has had limited
application in marine mammals. Aquarium facilities are increasingly faced with the challenging
issues of inhibition of undesirable in-breeding, maintenance of genetic diversity, and management
of populations. This study involves a 19 year old female killer who has experienced 3
unsuccessful attempts at calf-rearing. A review of the future of this species at the Vancouver
Aquarium prompted an investigation into the logistics of temporary inhibition of estrus. Various
fertility management protocols were considered on the basis of safety, efficacy, logistics of
administration, and ease of monitoring. A synthetic progestin Altrenogest (Regu-mate) was chosen,
and was administered daily starting 20 days postpartum. The equine dosage of 0.044 mg/kg
Altrenogest was administered in her initial daily feed of herring. Monitoring of drug efficacy
was accomplished by measuring pregnanediol glucuronide (PdG) and estrone conjugates (EC) in daily
urine samples, and progesterone and B-17 estradiol in twice monthly serum samples. Ovarian
activity was minimal throughout the 375 days of treatment. Pregnanediol glucuronide (PdG) levels
ranged from 0.0 to 7.32 ng/mg creatinine (mean of 0.961), while estrone conjugates (EC) levels
ranged from 0.0 to 2.64 ng/mg creatinine (mean of 0.253). No classical estrus activity was
observed. However, from days 140 to 165 elevated levels of EC were measured along with aberrant
elevations of PdG. A final analysis of this particular aberration will be available with the
results from the radioimmunoassay of urinary luteinizing hormone. Sexual activity between the
male and female has not diminished. Clinical and hematological parameters remain normal. Interim
results suggest that the chemical contraceptive Altrenogest (Regu-mate) can provide reliable
inhibition of estrus in the killer whale. Ongoing studies are designed to investigate regulation
of the timing of estrus, long term cyclical contraceptive therapy, and measurement of serum
altrenogest levels in killer whales.